Plasma GLP-1 and GLP-2 levels are markedly increased in individuals with type 2 diabetes treated with a GcgR antagonist [21] as well as in GcgR-deficient mice [22]. This evidence concerns the gene GCGR and type 2 diabetes mellitus.